Recent developments in research
- LCRF Joins Lung Cancer Advocacy Organizations and 23andMe to Launch Lung Cancer Genetics Study to Advance Research
- Science Update | summer 2024
- CROWN trial findings presented at ASCO
- News from the ASCO Annual Meeting
- Accelerated approval for SCLC treatment
- LCRF expands Research Advocates group
- FDA approves alectinib for ALK+ NSCLC
- Tepotinib approved for MET exon 14
- Science Update | Spring 2024
Recent FDA approvals
- FDA approves alectinib for ALK+ NSCLC
- Recent FDA approval of combined therapy for initial treatment of EGFR-mutated NSCLC
- FDA approves repotrectinib for patients with advanced ROS-1 fusion non-small cell lung cancer
- FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC
- FDA approves Imjudo with Imfinzi and chemo
- FDA approves drug for HER-2 unresectable or metastatic NSCLC